PURPOSE: Given the high incidence of colorectal cancer (CRC), and the availability of procedures that can detect disease and remove precancerous lesions, there is a need for a model that estimates the probability of developing CRC across various age intervals and risk factor profiles. METHODS: The development of separate CRC absolute risk models for men and women included estimating relative risks and attributable risk parameters from population-based case-control data separately for proximal, distal, and rectal cancer and combining these estimates with baseline age-specific cancer hazard rates based on Surveillance, Epidemiology, and End Results (SEER) incidence rates and competing mortality risks. RESULTS: For men, the model included a cancer-negative sigmoidoscopy/colonoscopy in the last 10 years, polyp history in the last 10 years, history of CRC in first-degree relatives, aspirin and nonsteroidal anti-inflammatory drug (NSAID) use, cigarette smoking, body mass index (BMI), current leisure-time vigorous activity, and vegetable consumption. For women, the model included sigmoidoscopy/colonoscopy, polyp history, history of CRC in first-degree relatives, aspirin and NSAID use, BMI, leisure-time vigorous activity, vegetable consumption, hormone-replacement therapy (HRT), and estrogen exposure on the basis of menopausal status. For men and women, relative risks differed slightly by tumor site. A validation study in independent data indicates that the models for men and women are well calibrated. CONCLUSION: We developed absolute risk prediction models for CRC from population-based data, and a simple questionnaire suitable for self-administration. This model is potentially useful for counseling, for designing research intervention studies, and for other applications.
PURPOSE: Given the high incidence of colorectal cancer (CRC), and the availability of procedures that can detect disease and remove precancerous lesions, there is a need for a model that estimates the probability of developing CRC across various age intervals and risk factor profiles. METHODS: The development of separate CRC absolute risk models for men and women included estimating relative risks and attributable risk parameters from population-based case-control data separately for proximal, distal, and rectal cancer and combining these estimates with baseline age-specific cancer hazard rates based on Surveillance, Epidemiology, and End Results (SEER) incidence rates and competing mortality risks. RESULTS: For men, the model included a cancer-negative sigmoidoscopy/colonoscopy in the last 10 years, polyp history in the last 10 years, history of CRC in first-degree relatives, aspirin and nonsteroidal anti-inflammatory drug (NSAID) use, cigarette smoking, body mass index (BMI), current leisure-time vigorous activity, and vegetable consumption. For women, the model included sigmoidoscopy/colonoscopy, polyp history, history of CRC in first-degree relatives, aspirin and NSAID use, BMI, leisure-time vigorous activity, vegetable consumption, hormone-replacement therapy (HRT), and estrogen exposure on the basis of menopausal status. For men and women, relative risks differed slightly by tumor site. A validation study in independent data indicates that the models for men and women are well calibrated. CONCLUSION: We developed absolute risk prediction models for CRC from population-based data, and a simple questionnaire suitable for self-administration. This model is potentially useful for counseling, for designing research intervention studies, and for other applications.
Authors: Thomas R Fears; DuPont Guerry; Ruth M Pfeiffer; Richard W Sagebiel; David E Elder; Allan Halpern; Elizabeth A Holly; Patricia Hartge; Margaret A Tucker Journal: J Clin Oncol Date: 2006-05-25 Impact factor: 44.544
Authors: Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel Journal: J Natl Cancer Inst Date: 2007-05-02 Impact factor: 13.506
Authors: Andrew N Freedman; Daniela Seminara; Mitchell H Gail; Patricia Hartge; Graham A Colditz; Rachel Ballard-Barbash; Ruth M Pfeiffer Journal: J Natl Cancer Inst Date: 2005-05-18 Impact factor: 13.506
Authors: Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Xifeng Wu; Jie Lin; H Barton Grossman; Maosheng Huang; Jian Gu; Carol J Etzel; Christopher I Amos; Colin P Dinney; Margaret R Spitz Journal: J Clin Oncol Date: 2007-11-01 Impact factor: 44.544
Authors: Jane A Driver; J Michael Gaziano; Rebecca P Gelber; I-Min Lee; Julie E Buring; Tobias Kurth Journal: Am J Med Date: 2007-03 Impact factor: 4.965
Authors: Martha L Slattery; Abbie Lundgreen; Susan A Kadlubar; Kristina L Bondurant; Roger K Wolff Journal: Mol Carcinog Date: 2011-11-28 Impact factor: 4.784
Authors: Paul K J Han; Christine W Duarte; Susannah Daggett; Andrea Siewers; Bill Killam; Kahsi A Smith; Andrew N Freedman Journal: Patient Educ Couns Date: 2015-07-19
Authors: Mart Dela Cruz; Ramesh K Wali; Laura K Bianchi; Andrew J Radosevich; Susan E Crawford; Lisa Jepeal; Michael J Goldberg; Jaclyn Weinstein; Navneet Momi; Priya Roy; Audrey H Calderwood; Vadim Backman; Hemant K Roy Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-25 Impact factor: 4.254
Authors: Brian J Wells; Michael W Kattan; Gregory S Cooper; Leila Jackson; Siran Koroukian Journal: J Am Board Fam Med Date: 2014 Jan-Feb Impact factor: 2.657
Authors: Ji Yeon Kim; Yoon Suk Jung; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Kyu Yong Choi; Dong Il Park Journal: World J Gastroenterol Date: 2016-04-07 Impact factor: 5.742
Authors: Stephanie R Land; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-02-25 Impact factor: 4.254